Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, retaining the price target of $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors related to the promising results of Lexicon Pharmaceuticals’ sotagliflozin. At the European Society of Cardiology Congress 2025, Lexicon presented data showing that sotagliflozin significantly reduces cardiovascular risks in older heart failure patients. This is particularly important as the incidence of heart failure events, such as stroke and myocardial infarction, increases with age.
The analysis was based on pooled data from two Phase 3 clinical trials, SOLOIST-WHF and SCORED, involving nearly 12,000 participants. The trials demonstrated that sotagliflozin effectively reduced the rate of cardiovascular death, major adverse cardiovascular events, and hospitalizations for heart failure compared to placebo. These results were consistent across different age groups, reinforcing the drug’s efficacy and supporting the Buy rating.